Resource Summary Report

Generated by NIF on Jul 28, 2026

Rat Anti-CD45 Monoclonal Antibody, PE-Cy7 Conjugated, Clone 30-F11

RRID:AB_394489
Type: Antibody

Proper Citation

BD Biosciences Cat# 552848, RRID:AB_394489

Antibody Information

URL: http://antibodyregistry.org/AB_394489

Proper Citation: BD Biosciences Cat# 552848, RRID:AB_394489

Target Antigen: CD45

Host Organism: rat

Clonality: monoclonal

Comments: Flow cytometry

Antibody Name: Rat Anti-CD45 Monoclonal Antibody, PE-Cy7 Conjugated, Clone 30-F11

Description: This monoclonal targets CD45

Target Organism: mouse

Clone ID: 30-F11

Antibody ID: AB_394489

Vendor: BD Biosciences

Catalog Number: 552848

Record Creation Time: 20250820T061054+0000

Record Last Update: 20250820T232821+0000

Ratings and Alerts

- Used for immunofluorescence microscopy assay by the Human Islet Research Network community. Contact(s): Feorillo Galivo, Markus Grompe - Human Islets Research Network https://hirnetwork.org/

No alerts have been found for Rat Anti-CD45 Monoclonal Antibody, PE-Cy7 Conjugated, Clone 30-F11.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 51 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Zhou P, et al. (2026) Targeting senescent EGR1+ B cells enhances immunotherapy efficacy in esophageal squamous cell carcinoma. Cell reports. Medicine, 102532.

Lowe E, et al. (2025) Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity. The Journal of pharmacology and experimental therapeutics, 392(8), 103634.

Zhou K, et al. (2025) M1-like macrophages regulate T cell infiltration in colorectal cancer through P2X4 receptor. iScience, 28(10), 113517.

Gao Y, et al. (2025) Trilaciclib triggers a neutrophil-related immune response and sensitizes non-small cell lung cancer to anti-PD-1 therapy. Cell reports. Medicine, 6(11), 102434.

Wang F, et al. (2025) Pseudouridine synthase 1-targeted therapy activates antiviral immunity to boost cancer immunotherapy. Cell reports, 44(9), 116233.

Rotini A, et al. (2025) Sympathetic innervation maintains the murine quiescent skeletal muscle stem cell pool via perivascular-derived Angpt1. Developmental cell.

Tian M, et al. (2025) Deconstructing the intercellular interactome in vascular dementia with focal ischemia for therapeutic applications. Cell.

Kim U, et al. (2025) Protocol to detect neutral lipids with BODIPY staining in myeloid-derived suppressor cells in mouse mammary tumors. STAR protocols, 6(1), 103485.

Vasquez JH, et al. (2025) Somatic Miwi2 modulates mitochondrial function in airway multiciliated cells and exacerbates influenza pathogenesis. iScience, 28(4), 112291.

Ishida T, et al. (2025) Differentiation latency and dormancy signatures define fetal liver hematopoietic stem cells at single-cell resolution. Cell reports, 44(10), 116289.

Xu Y, et al. (2025) Sensitized mast cells for targeted drug delivery and augmented cancer immunotherapy. Cell.

Luo Y, et al. (2024) Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell, 187(18), 4905.

Kim U, et al. (2024) ?Np63 regulates MDSC survival and metabolism in triple-negative breast cancer. iScience, 27(4), 109366.

Russick J, et al. (2024) Tumor stage-driven disruption of NK cell maturation in human and murine tumors. iScience, 27(11), 111233.

Zhang W, et al. (2024) Local adaptive immunity in atherosclerosis with T cell activation by aortic dendritic cells accelerates pathogenesis. iScience, 27(11), 111144.

Singh SS, et al. (2024) Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity. Molecular cancer therapeutics, 23(12), 1827.

Perrin S, et al. (2024) Single-nucleus transcriptomics reveal the differentiation trajectories of periosteal skeletal/stem progenitor cells in bone regeneration. eLife, 13.

Liu L, et al. (2024) Oncolytic bacteria VNP20009 expressing IFN? inhibits melanoma progression by remodeling the tumor microenvironment. iScience, 27(4), 109372.

Yang C, et al. (2024) Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy. Cancer cell, 42(12), 2064.

Wang Z, et al. (2023) Enhanced glycolysis-mediated energy production in alveolar stem cells is required for alveolar regeneration. Cell stem cell, 30(8), 1028.